Tenderwize
Zurück zur Suche

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 186 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Mepolizumab, ATC R03DX09

60/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

20 / 100

Risikofaktoren

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for the active substance Mepolizumab (ATC R03DX09).
  • Contracts are open to all interested pharmaceutical companies under uniform terms.
Vollständige Zusammenfassung anzeigen

Open House model for non-exclusive discount agreements on Mepolizumab (ATC R03DX09) offered by AOK Rheinland-Pfalz/Saarland. Any pharmaceutical company with authorized and marketable Mepolizumab products in Germany can join. Contracts run up to 24 months from May 1, 2025 to April 30, 2027, with rolling join dates. The procedure is not subject to EU procurement law despite using a standard notice form. No estimated value is provided.

Risiken

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only authorized and marketable medicinal products in Germany may be supplied.
  • Proof of authorization and marketability required (Lauer-Taxe listing or AMIce database extract).

Certifications

  • For products not yet listed, additional documentation (e.g., approval certificate) must be provided.

Zuschlagskriterien

Lot 1

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Auftraggeber

Lose (1)

LOT-0001

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

Non-exclusive discount agreement for Mepolizumab. Any pharmaceutical company meeting eligibility can sign up. Contracts valid until April 30, 2027. The AOK reserves the right to replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
12 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
165250-2025

Dokumente (1)

Ähnliche Ausschreibungen